Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 1
1976 3
1977 8
1978 11
1979 6
1980 22
1981 16
1982 21
1983 28
1984 48
1985 48
1986 59
1987 36
1988 56
1989 51
1990 75
1991 40
1992 71
1993 74
1994 83
1995 73
1996 86
1997 79
1998 90
1999 96
2000 119
2001 103
2002 106
2003 131
2004 165
2005 153
2006 131
2007 129
2008 122
2009 103
2010 114
2011 104
2012 92
2013 95
2014 74
2015 69
2016 63
2017 57
2018 52
2019 45
2020 33
2021 29
Text availability
Article attribute
Article type
Publication date

Search Results

3,028 results
Results by year
Filters applied: . Clear all
Page 1
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators. Cuzick J, et al. Lancet Oncol. 2010 Dec;11(12):1135-41. doi: 10.1016/S1470-2045(10)70257-6. Epub 2010 Nov 17. Lancet Oncol. 2010. PMID: 21087898 Clinical Trial.
BACKGROUND: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early …
BACKGROUND: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastroz …
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Ruhstaller T, et al. J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26. J Clin Oncol. 2019. PMID: 30475668 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) and their sequences (2 years of one treatment plus 3 years of the other) for postmenopausal women w …
PATIENTS AND METHODS: BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD. Cuzick J, et al. Lancet Oncol. 2011 Jan;12(1):21-9. doi: 10.1016/S1470-2045(10)70266-7. Epub 2010 Dec 7. Lancet Oncol. 2011. PMID: 21145284 Free PMC article. Clinical Trial.
Randomisation was independently done for each of the two treatments (radiotherapy and tamoxifen), stratified by screening assessment centre, and blocked in groups of four. ...FINDINGS: Between May, 1990, and August, 1998, 1701 women were randomly assigned to radiotherapy a …
Randomisation was independently done for each of the two treatments (radiotherapy and tamoxifen), stratified by screening assessment …
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group. Smith IE, et al. J Clin Oncol. 2005 Aug 1;23(22):5108-16. doi: 10.1200/JCO.2005.04.005. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998903 Clinical Trial.
PURPOSE: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of neoadjuvant tamoxifen compared with anastrozole and with the combination of …
PURPOSE: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) trial was designed to test the …
CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y. Tamura K, et al. J Clin Oncol. 2020 Feb 20;38(6):558-566. doi: 10.1200/JCO.19.01412. Epub 2019 Dec 10. J Clin Oncol. 2020. PMID: 31821071 Free PMC article. Clinical Trial.
PURPOSE: In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. ...CONCLUSION: In patients with CYP2D6-variant alleles, increasing tamoxifen dosing did not achieve a higher PFS rate at 6 months. The CYP2D6 genotyp …
PURPOSE: In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. ...CONCLUSION: I …
Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant).
Chan CWH, Miaskowski C, McCarthy A, Waye MMY, Yeo W, So WKW, Choi KC, Tsui SKW, Chan JYW. Chan CWH, et al. Medicine (Baltimore). 2020 Feb;99(8):e19083. doi: 10.1097/MD.0000000000019083. Medicine (Baltimore). 2020. PMID: 32080081 Free PMC article. Clinical Trial.
In addition, we hypothesize that a relationship will exist between the severity of tamoxifen-induced symptoms and allelic variations in tamoxifen metabolism-related genes. ...DISCUSSION: The proposed study will evaluate for polymorphisms in gene(s) that are a …
In addition, we hypothesize that a relationship will exist between the severity of tamoxifen-induced symptoms and allelic variations …
Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RF, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R. Budd GT, et al. Clin Cancer Res. 1998 Mar;4(3):635-42. Clin Cancer Res. 1998. PMID: 9533531 Free article. Clinical Trial.
A nonsignificant decrease in serum insulin-like growth factor I levels was noted during treatment, but this trend was similar to that observed in three "control" patients treated with tamoxifen alone. When given with daily tamoxifen, the maximum tolerated dose of AT …
A nonsignificant decrease in serum insulin-like growth factor I levels was noted during treatment, but this trend was similar to that observ …
Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial.
Machado PRL, Ribeiro CS, França-Costa J, Dourado MEF, Trinconi CT, Yokoyama-Yasunaka JKU, Malta-Santos H, Borges VM, Carvalho EM, Uliana SRB. Machado PRL, et al. Trop Med Int Health. 2018 Sep;23(9):936-942. doi: 10.1111/tmi.13119. Epub 2018 Jul 11. Trop Med Int Health. 2018. PMID: 29924907 Free article. Clinical Trial.
RESULTS: A total of 38 subjects were included in the trial, 15 were treated with standard Sb(V) and 23 with the combination of tamoxifen and Sb(V) . Of the patients treated with the co-administration scheme, 12 received tamoxifen orally and 11 were treated with topi …
RESULTS: A total of 38 subjects were included in the trial, 15 were treated with standard Sb(V) and 23 with the combination of tamoxifen
Prevention of breast cancer.
Jones AL, Powles TJ. Jones AL, et al. Curr Opin Oncol. 1991 Dec;3(6):1024-8. doi: 10.1097/00001622-199112000-00008. Curr Opin Oncol. 1991. PMID: 1843103 Review.
It remains to be seen whether tamoxifen will act as a true preventive agent or whether it will merely delay the appearance of breast cancer, in which case the use of the drug may alter the natural history of the disease in women who have been exposed to tamoxifen. . …
It remains to be seen whether tamoxifen will act as a true preventive agent or whether it will merely delay the appearance of breast …
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis.
Babu S, Macklin EA, Jackson KE, Simpson E, Mahoney K, Yu H, Walker J, Simmons Z, David WS, Barkhaus PE, Simionescu L, Dimachkie MM, Pestronk A, Salameh JS, Weiss MD, Brooks BR, Schoenfeld D, Shefner J, Aggarwal S, Cudkowicz ME, Atassi N. Babu S, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):15-23. doi: 10.1080/21678421.2019.1672750. Epub 2019 Oct 14. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 31608711 Clinical Trial.
Methods: Sixty amyotrophic lateral sclerosis (ALS) participants were randomized 1:1:1 to creatine 30 g/day (CRE), tamoxifen 40 mg/day (T40), or tamoxifen 80 mg/day (T80), with matching placebo. ...
Methods: Sixty amyotrophic lateral sclerosis (ALS) participants were randomized 1:1:1 to creatine 30 g/day (CRE), tamoxifen 40 mg/day …
3,028 results